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Summary It has been suggested that the selective loss of E-cadherin expression can generate invasiveness in
human carcinoma cells and might be a predictor ofmetastasis. Frozen sections of samples from 44 patients, 43
with suspected large bowel cancer and one with a liver recurrence were examined for E-cadherin expression
using the antibody 6F9 specific for the human E-cadherin molecule. Twelve of the 40 patients with carcinoma
already had lymph node involvement at the time of surgery. Samples from the primary carcinomas of only
nine of these 12 patients showed reduced E-cadherin expression. However, the one lymph node with metastatic
spread examined did show reduced E-cadherin expression. Four of the 40 carcinoma patients had liver
involvement at the time of surgery. The primary carcinoma samples from only three of these four patients
showed reduced E-cadherin expression. In addition only two out of the three liver metastases examined
showed reduced expression. The primary carcinoma samples from seven patients with no evidence of tumour
spread also exhibited reduced expression. Overall, analysis of the data suggests that there is no absolute
correlation between reduced E-cadherin expression and tumour spread in carcinomas of the large bowel.
E-cadherin (also known as Arc-1, uvomorulin and cell CAM
120/80) is one of a group of functionally related, integral
membrane glycoproteins responsible for calcium-dependent
cell-cell adhesion. Cadherins are responsible for the move-
ment and rearrangement of cell collectives during embryo-
genesisi (Takeichi, 1988) and for the orderly structure of
differentiated tissue. Cell transfection studies with E-cadherin
cDNA in rodent systems have demonstrated directly that
cadherin molecules are involved in cell-cell binding (Naga-
fuchi et al., 1987; Mege et al., 1988). Moreover, Behrens et
al. (1989) demonstrated that epithelial cells deprived of their
E-cadherin function by the addition of anti-E-cadherin anti-
bodies, not only became less adhesive but became able to
invade collagen gels and embryonal heart tissue. Shimoyama
and co-workers (1989) also reported that colonies of cultured
epithelial cells became dissociated and mobile after the addi-
tion of anti-E-cadherin antibody.
Expression of E-cadherin has been studied in tissue sec-
tions from a variety of well and poorly differentiated human
tumours, but not those arising in the large bowel, using
immunohistochemical and immunofluorescence techniques
(Eidelman et al., 1989; Shimoyama et al., 1989; Pfisterer et
al., 1990; Shimoyama & Hirohashi, 1991a,b; Schipper et al.,
1991). For the most part, E-cadherin expression has been
shown to correlate with differentiation status, with lower
levels of expression being observed in poorly differentiated
tumours. This correlation with differentiation status has been
observed for ovarian carcinomas (Pfisterer et al., 1990) and
squamous carcinomas of the head and neck (Schipper et al.,
1991). Loss of E-cadherin expression has also been reported
in a poorly differentiated hepatocellular carcinoma (Shimo-
yama & Hirohashi, 1991a). However, exceptions to the rule
are ductal breast carcinomas (Personal communication, Pro-
fessor W. Birchmeier, University of Essen, Germany), where
invasive forms retain epithelial characteristics and express
E-cadherin, and gastric carcinomas where only a small sub-
group of diffuse, advanced, carcinomas show an absence of
E-cadherin staining (Shimoyama & Hirohashi, 1991b).
Cancer cells are known to show decreaesed intercellular
adhesiveness. Recently, Frixen et al. (1991) demonstrated
that the selective loss of expression of E-cadherin could be
correlated not only with de-differentiation but with increased
invasiveness in a spectrum of human tumour cells in culture.
Moreover, the invasive behaviour of de-differentiated carcin-
oma cells could be reversed by transfection with E-cadherin
cDNA (Frixen et al., 1991), suggesting a key role for E-
cadherin in the suppression of invasion. Unstable expression
of E-cadherin has been reported in a highly metastatic ovar-
ian carcinoma cell line (Hashimoto et al., 1989) and the
absence of expression in a grade IV hepatocellular carcinoma
that went on to metastasise (Shimoyama & Hirohashi,
1991a). An absence of E-cadherin expression has also been
reported in the lymph node metastases of squamous cell
carcinomas of the head and neck (Schipper et al., 1991).
Therefore can reduced E-cadherin expression be correlated
with the progression of tumours to the metastatic state?
Colorectal carcinoma has a clear step-wise progression
from normal through premalignant and malignant stages to
the metastatic state. Moreover, for colorectal cancer malig-
nant progression and prognosis are linked to the different-
iation status of the tumour. Well differentiated carcinomas
retain their epithelial tissue structure, show well developed
intercellular junctions and are only weakly invasive. Poorly
differentiated carcinomas on the other hand are characterised
by poor tissue structure, few intercellular junctions and a
more invasive phenotype. In addition to differentiation state,
in colorectal cancer the degree of tumour invasion into and
through the bowel wall are also strong prognostic indicators
(Dukes, 1936; Astler & Coller, 1954). The present study aims
to address whether or not reduced E-cadherin expression
correlates with either or both these existing prognostic indi-
cators or is itself a more accurate predictor of tumour
spread.
Materials and methods
Forty-three patients undergoing surgery for suspected adeno-
carcinoma and one patient with liver recurrence were entered
into the study. Each resection specimen was collected fresh
from the operating theatre and delivered to the pathology
department with minimum delay. Each specimen was exam-
ined by a pathologist and fresh samples from the carcinoma,
polyp or lymph node and corresponding normal mucosa
were obtained for 43 patients, and from a liver metastasis for
one patient. Following sampling, all specimens were fixed in
10% neutral buffered formalin for routine diagnostic histo-
pathology.
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All the samples to be assessed for E-cadherin expression
were snap-frozen in liquid nitrogen prior to storage to
-80°C. Eight frozen sections, at 6 ym, were prepared from
each sample. Sections 1 and 8 were stained with haematox-
ylin and eosin and analysed by the pathologist for degree of
differentiation. Sections 2 to 7 were used to investigate E-
cadherin expression. The purpose of the haematoxylin and
eosin staining was to eliminate any discrepancies in differ-
entiation between the samples used to assess E-cadherin ex-
pression and those samples for diagnostic histopathology,
that might arise as a consequence of tumour heterogeneity.
Immunofluorescent staining was performed on ethanol fix-
ed frozen sections using the monoclonal antibody 6F9
specific for the 80 kd tryptic fragment of the human E-
cadherin molecule, purified from the A-431 carcinoma cell
line (Frixen et al., 1991), kindly donated by Professor W.
birchmeier, University of Essen. The epithelial nature of the
material was confirmed by double staining with a pankeratin
antibody (DAKO). The secondary antibodies were fluoro-
scein isothiocyanate conjugated horse antimouse Ig (Vector
Laboratories) and rhodamine-conjugated swine-antirabbit Ig
(DAKO), for E-cadherin and keratin respectively. Ethanol
fixed coverslips containing cells from the RTl 12 human blad-
der carcinoma cell line were run as a positive control in
addition to the normal mucosa from individual cases. Sec-
tions exposed only to the fluoroscein and rhodamine con-
jugated secondary antibody were run as negative controls.
The intensity of fluorescence representative of E-cadherin
expression did vary depending on the specimen, the nature of
the tissue and the way the section was cut. However, the
demarcation between positive, intermediate or reduced E-
cadherin expression and no E-cadherin expression was unam-
biguous. Therefore for simplicity the sections were scored as
either positive (+), negative (-) or intermediate (±) for
E-cadherin expression.
In all cases the formalin fixed paraffin sections from the
primary tumours were reviewed by one pathologist to assess
degree of differentiation and presence or absence of vascular
invasion. Dukes staging was obtained from the diagnostic
reports. The E-cadherin expression from the corresponding
frozen sections was compared with these three parameters.
Results
E-cadherin expression was investigated in frozen sections of
samples taken from 44 patients with large bowel disease by
immunofluorescent staining techniques using the monoclonal
antibody 6F9 specific for the human E-cadherin molecule
(Frixen et al., 1991). In tissue staining positively for E-
cadherin expression the cells fluoresce along their lateral
margins when viewed under a fluorescent microscope at an
exciting wavelength of 490 nm (Figure la, b and c). The
epithelial nature of the tissue examined was confirmed by
double staining with a rhodamine 'tagged' anti-keratin anti-
body (viewed at an exciting wavelength of 540nm). The
samples comprised 40 carcinomas from 40 different patients
all with their corresponding normal mucosae. All of the
carcinomas were adenocarcinomas. For three of the car-
cinoma samples there were the corresponding polyp samples
and for two there were the corresponding liver metastases
(see Table I). In addition there was one lymph node with the
corresponding normal bowel mucosa, two polyps from differ-
ent patients with their corresponding normal mucosae and a
liver metastasis sample.
Twelve of the 40 patients with carcinoma had lymph node
involvement at the time of surgery (Table I). However, the
carcinoma samples from only nine of these patients showed
reduced E-cadherin expression (Table II). The carcinoma
samples from the remaining three patients showed strong
E-cadherin expression. The only lymph node with metastatic
involvement examined showed reduced expression (Table I,
patient 5). Four of the 40 carcinoma patients already had
liver involvement at the time of surgery. This was subse-
quently confirmed histopathologically. However, the carcin-
oma samples from only three of these patients showed
reduced E-cadherin expression. Also, only two out of the
three liver metastasis samples examined showed reduced
staining (Table I). Overall, of the 18 primary carcinomas that
showed reduced expression only 11 had metastatic disease
(Table I). All the corresponding normal mucosae were posi-
tive for E-cadherin expression. Analysis of E-cadherin expres-
sion relative to differentiation status for the 40 primary
carcinoma samples from 40 patients, (Table III) showed the906 A.R. KINSELLA et al.
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Figure 1 Immunofluorescent staining for E-cadherin expression of a, the normal colonic mucosa, b, the adenocarcinoma and c, the
liver metastasis from a single patient (Patient 44, Table I) using the monoclonal antibody 6F9.
expression of E-cadherin to be reduced in all four frozen
sections of poorly differentiated material. Reduced E-cad-
herin expression was also seen in a poorly differentiated
lymph node metastasis (BT5) and in a poorly differentiated
liver metastasis (BT39). Twelve of the 30 moderately differ-
entiated tumours and two well differentiated tumours also
showed reduced staining. In the two patients where the cor-
responding liver metastases were available, the differentiation
status and E-cadherin expression were identical to those seen
in the primary carcinomas. Therefore although all the frozen
sections from the poorly differentiated tumours showed
reduced E-cadherin expression, reduced expression was also
observed in the frozen sections of 14 other tumours that were
not poorly differentiated (Table III).
Analysis of E-cadherin expression relative to Dukes' stage,
which currently provides the most widely used assessment ofE-CADHERIN EXPRESSION IN LARGE BOWEL CANCER 907
Table I Summary of E-cadherin expression in relation to clinical data for 44 patients who presented with symptoms of large bowel disease
Patient Sex Site Dir
BTI M Right M
BT2 M Sigmoid M
BT3 F Rectum W
BT4 M Sigmoid P
BT5 M LN P
BT6 F Polyp -
BT7 M Rectum M
BT8 M Right M
BT9 F Rectum M
BT1O F Sigmoid M
BTII M Sigmoid M
BT12 M Sigmoid W
BT13 M Right P
BT14 M Sigmoid M
BT15 M Sigmoid M
BT16 M Rectum W
BT17 M Rectum P
BT18 M Right M
BT19} M Polyp -
BT19) M Rectum M
BT20 F Caecum M
BT21 F Rectum M
BT22 M Colon P
BT23 F Rectum M
BT24 F Right W
BT25 F Sigmoid M
BT26 M Right M
BT27 F Rectum M
BT28 M Rectum M
BT29 M Sigmoid M
BT30 F Sigmoid M
BT31) M Polyp -
BT31) M Rectum M
BT32) F Polyp -
BT32) F Rectum M
BT33 M Polyp -
BT34 M Sigmoid M
BT35 F Sigmoid M
BT36 F Sigmoid M
BT37 F Right W
BT38 F Rectum M
BT39 M Liver M
Met.
BT40) M Rectum M
BT40) M Liver M
Met.
BT41 F Rectum P
BT41 M Right M
BT43 F Right W
BT44 M Sigmoid M
BT44 M Liver M
Met.
Dukes'
stage
C
B
B
C
A
B
C
C
B
B
C
B
C
A
C
B
B
C
C
B
B
B
A
B
B
B
B
B
A
B
A
C
B
A
B
Local invasion
Through wall
Through wall
Through wall
Through wall
Submucosa
Through wall
Through wall
Through wall
Through wall
Through wall
Through wall
Through wall
Muscularis propria
Muscularis propria
Through wall
Through wall
Through wall
Through wall
Through wall
Through wall
Through wall
Through wall
Muscularis propria
Through wall
Through wall
Through wall
Through wall
Through wall
Muscularis propria
Through wall
Submucosa
Through wall
Through wall
Submucosa
Through wall
C Through wall
C
B
B
B
Through wall
Through wall
Through wall
Through wall
Vascular Lymph node Liver involvement Other
invasion involvement at time ofsurgery polyps
Yes 1/10 0 3
No 0/11 0 0
No 0 0 0
No 1/7 0 0
No 0/3 0 3+
No 0/30 0 0
No 1/9 0 0
No 4/5 0 0
No 0/6 0 1
No 0/15 0 0
No 3/8 0 0
No 0 0 2
No 1/4 + 0
No 0 0 3+
Yes 9/9 0 1
No 0/7 0 0
No 0/10 0 1
No 1/8 0 0
No 1 0 0
No 0/9 0 0
No 0/10 0 3
No 0/7 0 0
No 0/12 0 0
No 0/9 0 0
No 0/6 0 3+
Yes 0 0 0
No 0 0 2
No 0/17 + 0
No 0/9 0 4
No 0/3 0 29
No 0 0 0
No 4/7 0 0
Yes 0/8 0 0
No 0/5 0 2
No 0/2 0 0
~~+_
No 4/4
Yes 7/10
Yes 0/1
No 0/10
No 0
E-cadiaerin
6Fh9
+
+
+ *d
+
+d
+
*
+
+
+
+
±+*
+
+*
+ 5 +
+ +
0
0
0
+
0
0
0
3
+*
+ ,W, MandPdenotewell,moderatelyandpoorlydifferentiated respectively; *Denotesrecurrentdisease;*dDenotesdiedfromrecurrentdisease;
**Denotes metastastic spread to sites other than the lymph nodes and liver.
tumour spread in large bowel tumours, shows only nine of
the carcinomas from the 12 Dukes C patients, with tumour
spread to the lymph nodes only, to show reduced E-cadherin
expression (Table IV). Only seve of the 22 Dukes' B patients
and two of the six Dukes' A patients showed reduced E-
cadherin expression. Of the 42 patients studied with malig-
nant disease, to date only three have died from recurrent
disease (Table I, patients 3, 13 and 17) and only one (patient
Table H E-cadherin expression in the 12 primary carcinoma patients
with lymph node involvement at time of surgery
E-cadherin expression No. patients
+ 3
+ 2
7
Proportion with reduced E-cadherin expression 9/12
35) has a recurrence. The carcinoma from patient 3 was well
differentiated and showed high levels of E-cadherin expres-
sion, whilst the carcinomas from patients 13 and 35 were
Table HI E-cadherin expression relative to differentiation status in
samples from the 40 primary carcinomas
Differentiation*
E-cadherin expression W M P
+ 4 18 0
+ 0
2
Proportion with reduced E-cadherin 2/6
expression
3
9
12/30
2
2
4/4
*W, M and P denot well, moderately and poorly differentiated
respectively. Wherecorresponding liver metastases were available they
had the same differentiation status as the carcinoma and exhibited
identical patterns ofexpression.908 A.R. KINSELLA et al.
TableIV E-cadherinexpressionrelativetoDukes' stageintheprimary
carcinoma samples from 40 patients
Dukes' stage
E-cadherin expression A B C
+ 4 15 3
+ 0 3 2
2 4 7
Proportion with reduced E-cadherin 2/6 7/22 9/12
expression
poorly and moderately differentiated respectively, already
had lymph node involvement and showed no E-cadherin
expression. Three patients (Table I, patients 28, 36 and 42)
had metastatic spread to sites other than the liver or lymph
nodes. The primary carcinomas for patients 28 and 42
expressed E-cadherin whilst that of patient 36 showed
reduced expression. There was no correlation between E-
cadherin expression and local invasion into and through the
bowel wall or with vascular invasion.
Discussion
The aim of the present study was to evaluate the usefulness
of reduced E-cadherin expression as a marker or predictor of
large bowel tumour cell invasion or metastasis. However, the
data summarised in Table II demonstrate that the primary
carcinomas of only nine of the 12 patients with lymph node
metastases show reduced E-cadherin expression. The primary
carcinomas from only three of the four patients with liver
involvement show reduced expression. Overall only 11 of the
17 patients with tumour spread at the time of surgery, (Table
I) exhibited reduced E-cadherin expression. There was no
absolute,correlation for reduced E-cadherin expression with
differentiation status (Table III) or Dukes' stage (Table IV)
the classic prognostic indicators. The difference between the
proportion of Dukes' C patients with reduced staining vs the
proportion for Dukes' A and B patients (Table IV) was 43%
with the 95% confidence interval ranging from 13 to 72%.
One could interpret the fact that some of the carcinomas,
with lymph node involvement (Table II) and tumour spread
to other sites, showed high E-cadherin expression because the
assay wasn't sensitive enough to pick up the few negative
staining cells that might result in metastatic foci. Alterna-
tively, the tumour sample selected for study might not have
contained negatively staining (metastatic cells) due to tumour
heterogeneity or the E-cadherin although expressed might not
have been functional (Hirano et al., 1992).
However, the large number of carcinomas that exhibit no
or reduced E-cadherin expression that have no evidence of
tumour spread (Table IV) belies this. Moreover, the strong
E-cadherin expression in the liver metastasis Figure lc of the
primary carcinoma of patient 44, Figure lb, would also tend
to disagree with this interpretation. Certainly the observation
that the pattern of E-cadherin expression was different in the
three patients (Table I, 28, 26 and 42) with metastatic spread
and in the three patients (Table I, 3, 13 and 17) that have
succumbed to recurrent disease, suggests that irrespective of
whether or not reduced E-cadherin expression correlates with
metastatic disease the routine immunofluroescent staining of
tissue sections is not precise enough to be used as part of
routine pathology.
Overall, one has to conclude that reduced E-cadherin ex-
pression is observed more frequently with tumour spread, but
in isolation reduced E-cadherin expression is probably not a
predictor of metastatic potential in large bowel tumours. A
significant proportion of the tumours that stain negatively
and therefore would if the hypothesis was accurate contain
large numbers of invasive or metastatic cells, have no
evidence of metastatic spread or rapid recurrent disease at
the present time. Obviously long-term the outcome and
disease free intervals for all the patients need to be con-
sidered. Patient I in the series was only operated on 18
months ago and more meaningful results will be obtained
once follow up gets out to 5 years. However, these prelim-
inary observations would seem to support the observations of
Shimoyama and co-workers that there is no simple relation-
ship between E-cadherin expression and increased invasive-
ness for all human carcinomas (Shimoyama et al., 1989;
Shimoyama & Hirohashi, 1991b). Tumour cell invasion and
metastasis is known to be a complex process and it may be
that other critical gene products such as nm23 (Steeg et al.,
1991), CD44 (Anstee et al., 1991) and components of the
cytoskeleton have a critical role to play in the process in
certain tumour types.
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